Patrik Brundin joined the Van Andel Institute in 2012, where he is deputy chief scientific officer and directs the Parkinson’s Disease (PD) Center. He earned a PhD in 1988 and an MD in 1992 from Lund University, Sweden and is highly cited in neuroscience with more than 400 publications on PD and related topics. His research focuses on pathogenic mechanisms of PD and development of therapies that repair damaged brain circuits and slow or stop disease progression. He has 40 years of experience in neural transplantation research, including clinical trials. He is a member of the board of directors for the World Parkinson Coalition and the executive scientific advisory board of The Michael J. Fox Foundation. He also serves as co-editor-in-chief of the Journal of Parkinson’s Disease and chair of the International Linked Clinical Trials scientific committee.
A Novel Preclinical Candidate for Reducing Alpha-synuclein Aggregation in Parkinson’s Disease
Phase 1b Trial to Assess the Safety and Efficacy of Dopamine Cell Transplants in Parkinson’s Disease Linked to Mutations in Parkin
Targeting the Chemical Modification of DNA to Suppress Neurodegeneration in Parkinson’s Disease